A whole genome association study was performed in a phase 3 clinical trial conducted to evaluate a novel antipsychotic, iloperidone, administered to treat patients with schizophrenia. Genotypes of 407 patients were analyzed for 334 563 single nucleotide polymorphisms (SNPs). SNPs associated with iloperidone efficacy were identified within the neuronal PAS domain protein 3 gene (NPAS3), close to a translocation breakpoint site previously observed in a family with schizophrenia. Five other loci were identified that include the XK, Kell blood group complex subunit-related family, member 4 gene (XKR4), the tenascin-R gene (TNR), the glutamate receptor, inotropic, AMPA 4 gene (GRIA4), the glial cell line-derived neurotrophic factor receptor-alpha2 gene (GFRA2), and the NUDT9P1 pseudogene located in the chromosomal region of the serotonin receptor 7 gene (HTR7). The study of these polymorphisms and genes may lead to a better understanding of the etiology of schizophrenia and of its treatment. These results provide new insight into response to iloperidone, developed with the ultimate goal of directing therapy to patients with the highest benefit-to-risk ratio.
Introduction
Schizophrenia is a psychotic disorder affecting approximately 1% of the population. 1 It is characterized by the presence of positive symptoms (unusual thoughts or perceptions, including hallucinations and delusions), negative symptoms (social withdrawal, lack of pleasure in everyday life) and impaired cognitive functions (verbal memory, information processing). A number of drugs have been approved to treat this chronic illness. However, patient response to treatment remains highly variable, 2, 3 and the discontinuation rate with antipsychotic treatment is high. 4 No single antipsychotic agent offers optimal effect for every patient with schizophrenia. Few data are available to guide clinicians and patients in the selection of the most appropriate medication, and in improving the treatment specificity for an individual patient. 5 Pharmacogenomics provides the opportunity to discover genetic markers predictive of response. Knowing how a patient with schizophrenia might respond to a particular therapy based on his or her genetic makeup may enable clinicians to select the most optimal drug and dosage with less trial and error.
Iloperidone is an investigational drug that has some of the receptor-binding characteristics of current atypical antipsychotics, such as a high 5-HT 2A /D 2 binding ratio, which predicts a tolerability profile better than that of typical antipsychotic agents. [6] [7] [8] [9] It also has receptor-binding characteristics that distinguish it from other atypical antipsychotics, including high affinity for a 2C -adrenergic receptors, which may result in antidepressant and anxiolytic activity and in improved cognitive function. 6, 7 Additionally, it has a low affinity for histamine receptors, which may reduce the risk for sedation and weight gain. 6, 8 Iloperidone treatment is associated with a low incidence of clinically notable weight gain, low rate of extrapyramidal symptoms and akathisia, and minimal prolactin elevations. [10] [11] [12] Iloperidone is rapidly absorbed in humans and extensively metabolized in the liver via multiple pathways, including pathways mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4. Furthermore, a pharmacokinetic-pharmacodynamic relationship for the efficacy of iloperidone has been established: statistically significantly greater proportions of responders (X20% improvement from baseline) in iloperidone-treated patients had average plasma concentrations X5 ng ml À1 compared with those with < 5 ng ml À1 . 13 A particular challenge in searching for genetic markers of response to antipsychotic treatment, especially in double-blind, placebo-controlled studies, is that patients are prone to drop out early if they experience unsatisfactory results before reaching therapeutic steady state concentrations of the active drug. Two methods have been used to deal with missing values from patient dropout. The first method, known as last observation carried forward (LOCF), replaces a patient's missing measurements at the end of the study with the last recorded measurement. LOCF has been used extensively in regulatory settings despite recognized biases. In particular, LOCF, which assumes that response of a droppedout patient remains constant from the last observed value to the end of the trial, tends to bias efficacy estimates. It also ignores trends over time and fails to account for missing-data uncertainty. [14] [15] [16] [17] The second method, called mixed-effects model repeated measures (MMRM) analysis, which facilitates unbiased estimates of postdropout behavior, was recently developed to estimate efficacy parameters directly from incomplete data. 18 We report here on the results of a whole-genome association study (WGAS) of the efficacy response of the novel atypical antipsychotic iloperidone in a phase 3 trial using both the LOCF and the MMRM methods. This clinical trial was a randomized, double-blind, placebo-controlled and ziprasidonecontrolled multicenter study conducted to evaluate the efficacy, safety, and tolerability of a 24 mg per day dose of iloperidone administered as 12 mg twice a day for 28 days to patients with schizophrenia in acute exacerbation. We identified several single nucleotide polymorphisms (SNPs) associated with iloperidone efficacy. Further study of these polymorphisms and of associated genes may lead to better understanding of the etiology of schizophrenia and of patient responses to antipsychotic treatments.
Materials and methods

Ethical conduct of the study
The clinical study was conducted in accordance with the Declaration of Helsinki; with the US Code of Federal Regulations governing the protection of human subjects (21 CFR 50), Institutional Review Boards (21 CFR 56) , and the obligations of clinical investigators (21 CFR 312); and with the International Conference on Harmonisation Guidance for Good Clinical Practice (Topic E6).
Patients and study design Patients 18-65 years of age with diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edn 1 were eligible to participate in a randomized, double-blind, placeboand ziprasidone-controlled, 28-day study of the efficacy and safety of iloperidone. Patients were randomly assigned to iloperidone 12 mg twice a day, ziprasidone 80 mg twice a day (active control) or placebo. The primary efficacy variable was change from baseline to the last scheduled observation in Positive and Negative Syndrome Scale total (PANSS-T) score. Comparison of iloperidone response to placebo response was performed to ensure the interpretation of the results and to comply with requirements of regulatory agencies.
PANSS measurements
During the course of the clinical trial, the PANSS score was assessed at baseline and on days 7, 10, 14, 21 and 28 or at the last visit when early termination occurred ( < 36% of patients). The PANSS ratings were only completed by a qualified MD, DO, PhD, PharmD, BA, BS or trained health care professional. Only those raters who had been qualified by United BioSource Corporation (Bethesda, MD, USA) were allowed to rate in this study. Raters were to have a minimum of 1 year of experience using these scales or comparable rating instruments in rating patients with psychiatric disorders. Each site had to have at least two certified raters for PANSS. Furthermore, interrater reliability tests were undertaken. For prequalification, raters were asked to view video recordings of patient interviews and complete rating of all items. At an investigators' meeting, all potential raters were further trained until acceptable results were achieved. Interview skills were also assessed for all raters. Furthermore, while the study was in progress, refresher training was conducted, and new training tapes were sent out to each site for rater reevaluation at appropriate intervals. All the new raters were required to be trained.
Pharmacogenomics population
Participation in the WGAS was optional, and written informed consent was required. Blood samples were collected, and quality genotype obtained (Quest Diagnostics Laboratories, Van Nuys, CA, USA) from 426 of 457 patients who consented to the optional WGAS, including 218 patients administered iloperidone, 103 treated with the active comparator and 105 who received placebo. The modified intent-to-treat (ITT) population contained all randomized patients who received at least one dose of double-blind study medication and from whom a baseline PANSS score measurement was obtained and at least one postbaseline PANSS efficacy measurement was obtained while on study medication. The ITT population used for the analysis consisted of 407 patients, including 210, 98 and 99 patients who received iloperidone, ziprasidone or placebo, respectively. More than 64% of patients completed the 28-day period.
Sex and race of patients
The iloperidone-treated patients of the ITT population included 174 men (83%) and 36 women (17%). Races were described as Asian (N = 17, 8%), black or African-American (N = 105, 50%), white (N = 80, 38%) or other (N = 8, 4%). This race assignment was consistent with the population structure inferred from the genotype data from more than 6000 random loci tested as previously described. 19 
Statistical analysis
Two-phase approach. To independently discover and confirm biomarkers of iloperidone efficacy, we randomly separated patients who were administered iloperidone and who were genotyped for the WGAS into two groups, Group 1 (discovery phase) and Group 2 (confirmatory phase). We used PROC SURVEYSELECT (SAS Institute, Cary, NC, USA) to stratify the groups to have approximately equal numbers of patients of each race and each sex. In Group 1 (106 patients), each SNP was tested for potential association between genotype and change in PANSS-T between patients in the low 30% (N = 30) and the high 30% (N = 32) extremes of the distribution of day 28 LOCF data. The 30% threshold allowed the selection of more than 30 samples at each extreme that represents patients with distinct efficacy phenotypes (mean change in PANSS-T À29.5 and þ 9.2 for the low and high 30%, respectively). Calculation was done to estimate the power to detect a significant difference between distinct genotype classes for the two extremes of the distribution, based on the change in PANSS-T and standard deviation (s.d.) observed in the extremes of Group 1. The difference change in PANSS-T between the two extremes (D) was 38.7 points, and the average s.d. was 9.9. We conducted a conservative power analysis assuming higher s.d. (15 and 20) , and weaker differences in PANSS-T change (20 and 25 points Single-phase approaches. Two separate methods were applied. LOCF data for PANSS-T were used in a one-way ANOVA of each SNP. Each genotype class was tested for association with change in PANSS-T between baseline and day 28 against the class of the other two genotypes combined; results from the ANOVA dictated the parsimonious genetic model to be used for additional testing. MMRM analysis was subsequently conducted using the parsimonious genetic model of each SNP in the MMRM model, as used for the analysis of the clinical trial results. 11 In this MMRM analysis, only the best genetic model of each SNP, as determined in the ANOVA LOCF data analysis, was used. For each SNP, the null hypothesis tested was that there was no difference in mean PANSS-T change from baseline between patients of different genotype classes. The PANSS-T score was considered as a continuous variable. Total scores were assumed to be missing at random (MAR) and the change from baseline in PANSS-T rating was analyzed using a MMRM model that included the following time points: day 7, day 10, day 14, day 21 and day 28 (end of study or early termination). MMRM model was conducted in SAS using PROC MIXED through generalized least squares estimation. Models included no intercept term, the three-way products of an indicator for SNP (as dichotomized by genotype class) with dummy indicators for each treatment group and dummy indicators for each time point (days 7, 10, 14, 21 and 28) to allow arbitrary trends across time, as well as covariates for centered baseline response for each of the five time points and dummy indicators for pooled center. Under this coding scheme, the coefficient of each treatment group Â time point indicator Â SNP was the estimated mean change scores for that treatment group and time point and SNP, adjusted for heterogeneity at baseline and heterogeneity among centers. Specified covariance structure was implemented by REPEATED statement using Type = Unstructured with covariance parameters estimated by restricted maximum likelihood.
Statistical correction for multiple testing. In the confirmatory step of the two-phase approach, Bonferroni corrections of a = 0.05/100 were applied. False discovery rate (FDR) corrections were also calculated using the Benjamini and Hochberg (BH) procedure. 20 Within each of the two single-phase analyses, the BH procedure was used; SNPs with the lowest P-values were analyzed without any specific threshold. FDR corrections were obtained from PROC MULTTEST (SAS Institute), which produces BH adjustments to original analytical P-values.
Genotyping methods
DNA samples were genotyped for more than 500 000 SNPs using a microarray set (GeneChip Human Mapping 500 K Array Set; Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. The set was composed of two arrays, each capable of genotyping on average 250 000 SNPs (B262 000 for Nsp arrays and 238 000 for Sty arrays).
Genetic markers of iloperidone efficacy C Lavedan et al DNA samples were also genotyped for additional polymorphisms previously studied for association with schizophrenia or antipsychotic treatment 3, [21] [22] [23] [24] [25] [26] [27] [28] but not represented on the microarray set. SNPs of interest were genotyped using either polymerase chain reaction (PCR) followed by restriction fragment length polymorphism detection or by allele-specific primer (ASP) PCR (see Table 1 ). Each PCR reaction contained 60 ng DNA, 1 Â PCR reaction buffer with MgSO 4 (0.5 mM), DNA polymerase (AmpliTaq; Applied Biosystems, Foster City, CA, USA), 5 pmol dNTP mix (Promega, Madison, WI, USA) and 10 pmol of each specific primer in a total volume of 25 ml. For the ASP assays, HotStarTaq polymerase (Qiagen, Valencia, CA, USA) was used, and two PCR reactions were performed for each sample, one for each allele. PCR conditions were as follows: 95 1C initial denaturation for 10 min, then 35 cycles of 30-s denaturation at 95 1C, 30-s annealing (temperature specific to SNP), 1-min extension at 72 1C and finally 10-min extension at 72 1C. PCR products were digested with the appropriate restriction enzyme and separated on a 4% agarose gel against standard DNA ladders to determine fragment sizes.
Genotyping data from individual PCR assays
Each genotype was determined independently by two scientists. Occasional absences of genotype call and ambiguities were resolved by repeat genotyping of the DNA sample.
Genotyping data from DNA arrays
To ensure the integrity of the data collected from DNA arrays, the following quality control steps were taken.
Algorithms. Each microarray was analyzed with the dynamic model-based genotyping algorithm 29 and with the latest Bayesian robust linear model with Mahalanobis (BRLMM) distance classifier with a confidence threshold of 0.5. 30 Under these conditions, missing genotypes were assumed MAR, and no imputation was made for any genetic data. Call rate. Call rate was defined for a single array as the percentage of SNPs that were called A/A, A/B or B/B by the BRLMM algorithm. Only arrays with X93% call rate were retained for further analysis.
Concordance between arrays. Of the more than 500 000 SNPs genotyped, 50 were common to both the Sty and the Nsp arrays. Only arrays with > 90% concordance for these SNPs were used in further analysis.
Uniqueness of samples. The B250 000 SNP data obtained per sample on each array (Sty or Nsp) were compared with the genotypes of all other samples to identify potential duplicate samples. If > 90% of the genotypes were identical between two arrays, DNA was retested to confirm genotypes and, if necessary, to eliminate duplicate samples.
Lack of DNA contamination. Lack of DNA contamination of a sample by another sample was assessed for each array by determining the overall percentage of SNPs with heterozygote calls, as calculated by the dynamic model-based algorithm. Genotype calls from arrays with < 30% heterozygote calls were considered to have come from a pure DNA sample. Only those arrays with < 30% heterozygote calls were used for further analysis.
Sex determination. For each DNA sample, sex was blindly determined by the BRLMM algorithm based on the percentage of heterozygosity of the SNPs on the X chromosome. The result was compared with the expected sex. In case of divergent data, a PCR-based assay for the amelogenin gene (AMELX) was performed on the original sample and on a new DNA aliquot. A new genotyping experiment was performed with the Sty and Nsp arrays. Samples with incompatible results were excluded from the WGAS.
Allele frequency. This project was focused on the most common polymorphisms by selecting SNPs with minor allele frequency X10%. This 10% cutoff is commonly used in genome-wide studies [31] [32] [33] as it reduces the number of SNPs that cannot add information given the power of the study. It also raises the proportion of SNPs with high informativity and increases the chance to observe all three genotype for most SNPs.
SNP selection. A reference DNA (Human Genomic DNA 103 Control; Affymetrix) with available genotypes for SNPs on the microarray set was systematically tested in parallel with the patient samples. Eight DNA 103 replicates for the Sty and Nsp arrays were obtained and analyzed. Individual SNP assays were considered to make accurate and reproducible calls (concordant calls) when the calls (A/A, A/B, B/B) were identical across the eight replicates and identical to the reference calls provided by Affymetrix. Only SNPs with 100% concordance for DNA 103 were retained for WGAS. Five SNPs that cross-hybridized with the Y chromosome and all SNPs on the X chromosome were not used. The total number of SNPs analyzed in this WGAS was 334 563.
Results
The effectiveness of iloperidone for the treatment of schizophrenia was assessed using PANSS, a standardized method commonly used in clinical studies of antipsychotics. Genetic association with the change in the PANSS-T between baseline and day 28 was tested for 334 563 SNPs. In an association study with such a large number of SNPs, the selection of the best Genetic markers of iloperidone efficacy C Lavedan et al Abbreviations: ASP, allele-specific primer; RFLP, restriction fragment length polymorphism; SNP, single nucleotide polymorphism. Gene names correspond to the NCBI official symbols. SNPs are identified by their unique dbSNP number (http://www.ncbi.nlm.nih.gov/projects/SNP/), when available. Their common designation in the literature is indicated between parentheses below the dbSNP number. Primer sequences are from 5 0 to 3 0 ; F and R refer to forward and reverse primers used in the PCR reaction, respectively (for ASP assays, 1 and 2 distinguish the allelespecific primers). Annealing temperature of each PCR reaction is indicated in degrees Celsius (1C). PCR product size after complete enzymatic digestion is shown for each allele in base pairs. a Primer sequences were previously reported. 25-28 b The SNP tested within the HTR1A gene was previously referred to as C(-1019)G 27 ; no dbSNP number is listed for this SNP.
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candidates is based on extreme P-values. These may be more sensitive than usual to the particulars of the statistical method used. Thus, to select the most likely markers of the efficacy of iloperidone, we used several analytical methods and focused on those SNPs with persistently low P-values across different methods. We performed three analyses. Analysis 1 was a two-phase approach in which DNA samples were separated into two groups. The first group consisted of 50% of the samples for a discovery phase in which only the top 30% and the bottom 30% of the change in PANSS-T (LOCF data) were used, and the second was a hold-out group consisting of the other 50% for a confirmatory phase. Only the 100 SNPs with the lowest P-values in the discovery phase were subsequently tested. A similar method was successfully applied recently to identify a genetic variant that modulates cardiac repolarization. 34 Analysis 2 was an ANOVA of LOCF data for all iloperidonetreated patients in a single-phase approach. Analysis 3 was an MMRM analysis of all patients using the most parsimonious genetic model of each SNP. The two single-phase approaches (analyses 2 and 3) provided more power to detect significant associations by taking advantage of all available samples.
Overall whole genome association results from the LOCF and MMRM single-phase approaches are shown in Figure 1 . Forty five of the 100 SNPs with the lowest P-values were common between these two analyses. Six of these SNPs were also among the top 100 SNPs of the two-phase analysis. We report in more detail on these six SNPs (rs11851892, rs9643483, rs875326, rs2513265, rs7837682, rs4528226) and their association with iloperidone response (Table 2) . Data from the different treatment groups were used in the MMRM statistical model, which allowed us to compare genotype effect between iloperidone treatment and placebo. Except when otherwise specified, results discussed herein refer to PANSS-T data and to P-values generated from the MMRM analysis.
NPAS3 and iloperidone response SNP rs11851892 is located on chromosome 14q12-q13 within intron 3 of the NPAS3 gene, which codes for the neuronal period/aryl hydrocarbon receptor/single-minded (PAS) domain protein 3. Three other SNPs within this gene were also significant at the P < 0.01 level (Figure 2a) . The non-G/G rs11851892 genotype, which had a frequency of 31%, was present in a group of iloperidone-treated patients who averaged > 20-point improvement from baseline in PANSS-T (-20.12 [ ± 3.69]), 68% greater than the mean response (-12.01 [±1.03]) of all iloperidonetreated patients (Table 3) . 11 Patients who carried the non-G/G genotype were approximately three times more likely to experience 20% improvement than Rank refers to SNP in each analysis when ordered from lowest to highest P-value. P-values of the discovery phase were obtained from the truncated nonparametric measure ANOVA, based on the Kruskal-Wallis test with genotype as the grouping variable, using the LOCF data on the extremes of the distribution of 50% of the patients treated with iloperidone. P-values of the confirmatory phase were obtained using independent group t-tests of the change in PANSS-T on Day 28 LOCF data for patients in iloperidone Group 2, before and after correction for multiple testing (100 SNPs) using the FDR method (BH-adjusted P). a ANOVA P-values were obtained with LOCF data of all iloperidone-treated patients before and after correction for multiple testing (BH-adjusted P). b P-values of the MMRM analysis were obtained between genotype classes among all iloperidone-treated patients before and after correction for multiple testing (BH-adjusted P).
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patients who carried the G/G genotype (odds ratio (OR) = 2.74, P = 0.0011; Table 5 ). The NPAS3 gene has previously been linked to schizophrenia. Kamnasaran et al. 35 described a mother and daughter with schizophrenia who were carriers of a chromosome translocation, t(9;14)(q34;q13). Two of the SNPs associated with change in PANSS-T in our study (rs11851892, rs17583667) were localized within the same intron 3 of NPAS3 as the breakpoint observed in this family (Figure 2a) (Table 3) . Patients who carried the non-G/G genotype were approximately 3.5 times more likely to experience 20% improvement than patients who carried the G/G genotype (OR = 3.42, P = 0.0009; Table 5 ).
SNP rs9643483 lies between the XK-Kell blood group complex subunit-related family, member 4 (XKR4) gene (B220 kb away) and the retinitis pigmentosa 1 (RP1) gene (B250 kb away). No other SNPs in that region were significant at the P < 0.01 level (Figure 2b) .
The XKR4 gene codes for a protein related to the XK protein. Kell and XK are two distinct red blood cell membrane proteins that form the Kell blood group Figure 2 Genetic association between change in PANSS-T score and SNPs in the NPAS3, XKR4, TNR, GRIA4, GFRA2 and NUDT9P1 gene regions. P-values (vertical axis) MMRM analysis are shown for the genomic regions containing NPAS3 (a), XKR4 (b), TNR (c), GRIA4 (d), GFRA2 (e) and NUDT9P1 (f) in order of the SNPs' physical locations (horizontal axis). The direction of the maps relative to the centromere and to the telomere is indicated by horizontal arrows. SNPs with Pp0.01 are boxed. The approximate location in NPAS3 of the breakpoint described by Kamnasaran et al. 35 in a family with schizophrenia is indicated by an asterisk (*). Abbreviations: cen, centromere; tel, telomere.
complex. XK is a putative membrane transporter whose substrate is unknown, but absence of the protein is associated with McLeod syndrome. 36 This rare, genetic, X-linked disease is characterized by red blood cell acanthocytosis and late-onset central nervous system (CNS) and neuromuscular abnormalities. CNS manifestations include cognitive impairment, psychopathology, seizures and choreatic movements. One report has mentioned schizophrenia as a manifestation of McLeod syndrome. 37 Mutations in the RP1 gene have been reported to cause dominant retinitis pigmentosa. The specific role of the protein encoded by this gene is still unknown, but it is thought to be important in photoreceptor biology. The association of retinitis pigmentosa with features of psychosis has been reported in patients with Usher syndrome, but it is not well understood. 38 No reports have been published of an association between XKR4 or RP1 and schizophrenia or response to antipsychotic treatment. TNR and iloperidone response Another SNP of interest is rs875326 on 1q25.1, located between the TNR (B2.5 kb away) and TNN genes (B170 kb away), which encode the tenascin-R and -N proteins, respectively. The genomic region between TNR and TNN also contains the KIAA0040 locus of still unknown function (Figure 2c) . The rs875326 homozygote genotypes were associated with the highest response to iloperidone treatment, with a mean change in PANSS-T of -16.39 ( ± 4.35) compared with a mean change of -6.21 (±4.51; P = 0.000021) for patients with the heterozygote genotype ( Table 3 ). More than 63% of iloperidonetreated patients homozygote for rs875326 were approximately 3.5 times more likely to experience 20% improvement than those who carried the A/G genotype (OR = 3.57, P < 0.0001; Table 5 ).
Tenascin-R is an extracellular matrix protein expressed primarily in the CNS and localized around motor neurons and on motor axons in the spinal cord, cerebellum, hippocampus and olfactory bulb. 39, 40 It is a member of the tenascin gene family, which includes at least three other genes in humans-TNN on 1q, TNC on 9q33 and TNXB on 6p21.3. TNXB deficiency leads to a clinically distinct, autosomal recessive form of Ehlers-Danlos syndrome, a severe connective tissue disorder. Two SNPs in the TNXB gene are associated with schizophrenia in a British population. 41 To date, no direct evidence has implicated TNR or TNN in schizophrenia or in the response to antipsychotic treatment.
GRIA4 and iloperidone response SNP rs2513265 is located on chromosome 11q22, approximately 58 kb from the 5 0 end of the glutamate receptor, inotropic, AMPA 4 (GRIA4) gene (Figure 2d) . The rs2513265 T/T genotype was present in approximately 23% of iloperidone-treated patients who, on average, experienced PANSS-T changes lower than those of patients with a different genotype (-3.30 [ ± 4.11] vs -15.22 [ ± 4.26] , respectively, P = 0.000055) and comparable to those of patients receiving placebo (Table 3) . Patients who carried the non-T/T genotype were approximately 2.5 times more likely to experience 20% improvement than patients who carried the T/T genotype (OR = 2.43, P = 0.011; Table 5 ). Two other SNPs, rs7930372 and rs4142579, located within approximately an 8-kb interval, were also significant at P < 0.01 (Figure 2d) . Interestingly, some haplotypes of the GRIA4 gene have shown a positive association with schizophrenia in the Japanese population.
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GFRA2 and iloperidone response SNP rs7837682 is located in the 8p21.3 region, where the schizophrenia susceptibility locus referred to as SCZD6 has been mapped through a number of positive genetic association studies. [43] [44] [45] The rs7837682 A/A genotype was associated with the highest response to iloperidone treatment, with a mean change in PANSS-T of -15.95 ( ± 4.23) compared with a mean change of -6.08 (±4.28; P = 0.00018) for patients with a different genotype (Table 3 ). More than 58% of iloperidone-treated patients who were homozygote A/A for rs7837682 were approximately three times more likely to experience 20% improvement than the patients who carried a different genotype (OR = 2.95; P = 0.0004; Table 5 ).
The closest known gene from rs7837682 is glial cell line-derived neurotrophic factor (GDNF) receptor-a2 (GFRA2), located approximately 360 kb away. Six other SNPs downstream of this gene were also significant at the P < 0.01 level, including four SNPs within approximately 15 kb (Figure 2e ). GFRA2 codes for GDNF receptor-b (GDNFR-b). GDNF plays a key role in the control of neuron survival and differentiation. Results from a study in an Italian population suggest that a 3 0 -UTR GDNF repeat polymorphism is associated with schizophrenia.
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NUDT9P1 and iloperidone response SNP s4528226 was the only SNP that showed a statistically significant association in the two-phase approach analysis at the P < 0.05 level after correction for multiple testing using either the Bonferroni method or the FDR method (Table 2 ). This SNP also showed the most significant statistical association when using all samples from the iloperidone-treated group, with either the LOCF method or the MMRM method ( Table 2 ). The rs4528226 G/T genotype was associated with the highest response to iloperidone treatment, with a mean change in PANSS-T of -18.73 ( ± 3.99) compared with a mean change of -6.61 ( ± 4.29; P = 0.00000078) for patients with a different genotype (Table 3 ). More than 47% of iloperidone-treated patients heterozygote for rs4528226 were three times more likely to experience a 20% improvement than homozygote patients (OR = 3.00, P = 0.0001; Table 5 ).
SNP rs4528226 is located on chromosome 10q23.31, close to the NUDT9P1 pseudogene, between the ankyrin repeat domain 1 (ANKRD1) gene and the polycomb group ring finger 5 (PCGF5) gene, approximately 200 kb from the serotonin receptor 7 (HTR7) gene (Figure 2f) . No other SNPs in the same chromosomal region showed a statistically significant association at the P < 0.01 level, including the closest flanking SNPs located 3.5 and 6.3 kb away. The HTR7 gene, which is considered a possible schizophrenia-susceptibility factor, has been associated with schizophrenia in a Japanese population. 47 No link has been reported between schizophrenia or the response to antipsychotic treatment and NUDT9P1, ANKRD1 or PCGF5.
Analysis of sex and race SNP allele frequencies can vary between races, and recombination rates depend on sex; therefore, we conducted ad hoc analyses of these potential confounding factors. For all SNPs reported herein, the association of a particular genotype with higher or lower response was consistent between men and women (data not shown) and across races ( Table 4 ), indicating that the significant associations observed Genetic markers of iloperidone efficacy C Lavedan et al were not attributable to a bias resulting from the heterogeneity of the patient population studied.
Analysis of PANSS subscales
We also conducted an MMRM analysis with these six selected SNPs in the following PANSS subscales: positive symptom subscale (PANSS-P), negative symptom subscale (PANSS-N) and general psychopathology subscale (PANSS-GP). For each SNP, a strong genotype effect on the change from baseline at day 28 was observed in the three subscales (Figure 3) . The most statistically significant differences were observed for PANSS-T and PANSS-P with rs4528226 (NUDT9P1; Figure 3f ). The lowest P-values for PANSS-N and PANSS-GP were obtained with rs2513265 (GRIA4; Figure 3d ) and rs875326 (TNR; Figure 3c ), respectively.
Odds ratio, sensitivity, specificity and predictive values of selected SNPs To better appreciate the potential clinical value of the markers in predicting response to iloperidone, we calculated OR, sensitivity, specificity and predictive values of each selected marker (Table 5) . SNP rs11851892 (NPAS3), which differentiated 31% of patients with superior iloperidone response, had the highest specificity (79%) and the strongest positive predictive value (65%). The two SNPs that differentiated a small group ( < 23%) of iloperidone-treated patients with lower changes in PANSS-T, rs9643483 (XKR4) and rs2513265 (GRIA4), had the highest sensitivity (88 and 85%, respectively). The other SNPs had intermediate values.
Validation of genotype calls
Genotype calls generated by the microarray set were also determined with PCR-based assays for the iloperidone-treated patients. We observed an accuracy rate of 100% for rs9643483 (XKR4), rs875326 (TNR), rs2513265 (GRIA4) and rs4528226 (NUDT9P1), 99.5% for rs11851892 (NPAS3), with only one erroneous call, and an accuracy rate of 96% for rs7837682 (GFRA2). Only 2 erroneous calls for rs7837682 were between different genotype classes (A/A vs non-A/A). Analysis of polymorphisms in candidate genes Several SNPs previously studied for possible association with schizophrenia or antipsychotic treatment response were genotyped for this WGAS using specifically designed assays (Table 1) . They included SNPs in the COMT, DRD2, DRD4, GRM3, HTR1A, HTR2A, NOS1 and SYN2 genes. 3, [21] [22] [23] [24] All other genes of interest were tested only for the SNPs represented on the microarray set. None of these SNPs showed significant association with change in PANSS-T at the P < 0.01 level in both single-phase LOCF and MMRM approaches.
Discussion
Through a WGAS performed in the context of a phase 3 clinical trial that investigated the efficacy, safety and tolerability of the novel atypical antipsychotic iloperidone, we identified several SNPs in six chromosomal regions significantly associated with efficacy response to iloperidone for the treatment of schizophrenia. These SNPs showed a significant genotype effect on the improvement of symptoms, after 4 weeks of treatment, in the PANSS-T scale as well as in the positive, negative and general psychopathology subscales (Table 3 ; Figure 3 ). SNP rs11851892, within the NPAS3 gene, identified a group of 31% of iloperidone-treated patients who experienced greater improvement in PANSS-T. Two independent linkage studies have suggested that a susceptibility locus for schizophrenia resides in chromosome 14q13. 44, 48 The NPAS3 gene, located on 14q12-q13, has already been linked to schizophrenia in a family in which a mother and a daughter with the illness were carriers of a t(9;14)(q34;q13) translocation with a breakpoint in intron 3. 35 Of the NPAS3 SNPs significantly associated with change in PANSS-T in our study, two were in intron 3, including rs11851892, which had the most significant association for that region (P = 0.000028 for ANOVA LOCF; P = 0.000093 for MMRM). The NPAS3 protein belongs to a family of transcription factors that contain a basic helix-loop-helix region followed by a PAS domain. Kamnasaran et al. 35 showed that the NPAS3 protein is expressed in multiple adult brain tissues, including the hippocampus, thalamus and cortex. They proposed that haploinsufficiency of NPAS3 played a role in schizophrenia in the family with the intron 3 breakpoint. Additional evidence supporting the potential role of NPAS3 in schizophrenia comes from recent studies of mice. Pieper et al. 49 showed that NPAS3-deficent mice manifest behavioral and neuroanatomic abnormalities reminiscent of schizophrenia. Erbel-Sieler et al. 50 demonstrated that NPAS3-homozygous adult mice had marked reductions in reelin in the cortex, dentate gyrus and amygdala. Reelin is an extracellular matrix protein thought to control cell-cell interactions critical for cell positioning and neuronal migration during brain development. In one genetic study, 51 it was suggested that reelin is associated with treatment-resistant schizophrenia, and it has been shown that levels of reelin and its mRNA are significantly reduced in several brain areas of patients with undifferentiated or paranoid schizophrenia. 52 Our results provide the first evidence of a possible link between NPAS3 and the efficacy of an antipsychotic treatment. This finding in iloperidone-treated patients underscores the importance of understanding the role of this transcription factor in the etiology of schizophrenia and in the efficacy of antipsychotics.
Of the other SNPs associated with change in PANSS-T in iloperidone-treated patients, several were of particular interest, including SNPs upstream of the GRIA4 gene. GRIA4 is a member of L-glutamate-gated ion channels, which mediate fast synaptic excitatory neurotransmission. This type of receptor is thought to modulate glutamatergic transmission in the brain by inhibiting glutamate release at the synapse. Although the specific AMPA4 glutamate receptor has not been extensively studied, an association between GRIA4 haplotypes and schizophrenia has been reported in a Japanese population. 42 This finding was not seen in a Chinese population, 53 and no studies of other populations have been reported. A potential role for glutamate in schizophrenia was first proposed based on the observation that the psychotomimetic agents phencyclidine (PCP) and ketamine induce psychotic symptoms and neurocognitive disturbances similar to those of schizophrenia by blocking neurotransmission at NMDA-type glutamate receptors. Since then, evidence of glutamate dysregulation in schizophrenia has been increasing. 54 Additionally, we found several SNPs associated with iloperidone efficacy upstream of the GFRA2 gene, located on 8p21.3. Numerous studies in different populations have indicated a genetic association between schizophrenia and chromosome 8p, particularly in the 8p21 region. [43] [44] [45] This schizophrenia susceptibility locus is referred to as SCZD6. Candidate genes in that region include neuregulin 1 (NRG1), adrenergic a-1A-receptor (ADRA1A) and frizzled homologue 3 (FZD3). Our findings suggest adding GFRA2 to the list of genes in that region, which may play a role in schizophrenia and antipsychotic treatment. The GFRA2 protein is a cellsurface receptor for GDNF and neurturin. Several Table 5 Odds ratios, sensitivity, specificity and predictive values of SNPs associated with change in PANSS-T in iloperidone-treated patients SNP Gene Genotype Improvement < 20% Improvement X20%
Odds ratio studies have linked GDNF to schizophrenia. In an animal study in which PCP was injected into rats to produce schizophrenia-like symptoms, Semba et al. 55 showed that PCP alters the function of GDNF in the ventral midbrain, where dopamine cell bodies are localized. Our results suggest that new studies should be undertaken to investigate the interplay of GDNF, neurturin and GFRA2 in the etiology of schizophrenia and in the response to antipsychotic treatments. Several SNPs identified in our study lay in intergenic regions, sometimes far away from any known gene. One such SNP is rs4528226, which showed the most statistically significant association with change in PANSS-T in all analyses ( Table 2 ; Figures 1 and 2f ). This SNP is located approximately 200 kb upstream from the HTR7 gene. Interestingly, it has been shown that iloperidone has high affinity for the 5-HT 7 receptor. 56 The biological relevance of SNPs located in intergenic DNA is currently difficult to assess. Although most genetic research has historically focused on coding sequences of genes and nearby promoter regions, comparative genomics studies are uncovering other functional genomic elements that can be located in introns and in gene-poor 'desert' regions sometimes hundreds or thousands of kilobases away from the genes they regulate. [57] [58] [59] It is possible that the intergenic SNPs examined in our study are within regulatory elements, response elements, transposable elements, noncoding RNAs, coding sequences or splicing sites that have not yet been identified. Alternatively, they may be in linkage disequilibrium with these elements or sequences. So far, no long-range cis-regulatory elements of HTR7 have been identified. Our results suggest that the genomic region of rs4528226 should be thoroughly examined for the presence of such elements.
We also analyzed nine SNPs in eight candidate genes because of their possible association with schizophrenia. None of them show a significant association (at P < 0.01) with iloperidone response. However, as the SNP coverage was not complete, these results do not exclude the possibility that these genes may be associated with the efficacy of iloperidone.
The etiology of schizophrenia remains largely unknown, and it is still unclear to what extend genetic factors involved in drug response may play a role in the predisposition to, or in the development of, the disease. It is expected that pathways involved in drug response may not necessarily overlap with disease mechanisms as exemplified by enzymes that metabolize multiple drugs across various indications. However, the study of polymorphisms in molecules believed to be involved in the etiology or the development of the disease as well as in its treatment, suggests possible overlaps between pathways of disease and drug response. In the case of schizophrenia, several dopamine and serotonin receptors have been implicated in both the mechanism of the disease and antipsychotic response. 60 The polymorphisms and genes identified in our study because of their association with iloperidone efficacy should therefore be further considered as potential players in the mechanism of schizophrenia. The six SNPs identified here should be further explored in subsequent studies; this will provide the opportunity to validate not only their individual clinical utility but also their potential combined value as predictors of efficacy.
In conclusion, we have identified several genetic polymorphisms associated with the efficacy of iloperidone for the treatment of patients with schizophrenia. The allele frequency of the SNPs uncovered here and their individual effects on treatment response should be considered in the design and evaluation of subsequent clinical studies with iloperidone or with other antipsychotic agents. Although our results highlight the genetic complexity of drug response, they also underscore the opportunity of this new kind of pharmacogenomic approach. In the near future, clinicians should be able to better estimate the individual risk-to-benefit ratios of various drugs based on each patient's genetic makeup and, with more assurance to determine the best treatment options.
